Verdiva Bio

About Verdiva Bio

Verdiva Bio is a clinical-stage cardiometabolic company focused on accelerating the development of differentiated medicines to address unmet medical needs in obesity and cardiometabolic disorders. Their mission is to transform lives by developing next-generation therapies that offer better outcomes through patient-friendly options, leveraging emerging science in gut-brain biology.

Products & Services

VRB-101 (Oral):An oral, once-weekly GLP-1 receptor agonist in clinical development for obesity, with compelling efficacy potential and confirmed viability for once-weekly dosing from a phase 1 study.

VRB-103 (Oral):An oral, once-weekly dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, as monotherapy or in combination with oral GLP-1 therapy.

VRB-103 + VRB-101 (Oral):An oral daily or once-weekly combination therapy of VRB-103 and VRB-101 in preclinical development for obesity.

Specialties

Cardiometabolic Health Obesity Treatment Gut-Brain Biology GLP-1 Receptor Agonists Amylin Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 411000000 MR: - FA: $411M FAN: 411000000	D: 2025-01-09 FD: 2025-01-09	7 investors

Series A Latest

2025-01-09

$411.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark Pruzanski

Board Chair

W

Weidong Zhong

Chief Strategy Officer

E

Elaine Johnston

General Counsel

A

Andrew Prosser

Senior Vice President, Head of Finance

T

Tapan Maniar

Chief Business Officer

A

Ashley Taylor

Chief Technology Officer

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Verdiva Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised